Anti-COL18A1 antibody [EPR23481-240],Abcam,AB275390

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

ICC/IF, Flow Cyt (Intra), IP, WB

Platform ID

BAB328497861

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-COL18A1 antibody [EPR23481-240]
Cat. No.AB275390
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationICC/IF, Flow Cyt (Intra), IP, WB
ClonalityMonoclonal
Clone NumberEPR23481-240
Concentration0.413 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Probably plays a major role in determining the retinal structure as well as in the closure of the neural tube.. Non-collagenous domain 1. May regulate extracellular matrix-dependent motility and morphogenesis of endothelial and non-endothelial cells; the function requires homotrimerization and implicates MAPK signaling.. Endostatin. Potently inhibits endothelial cell proliferation and angiogenesis (PubMed : 9459295). May inhibit angiogenesis by binding to the heparan sulfate proteoglycans involved in growth factor signaling (By similarity). Inhibits VEGFA-induced endothelial cell proliferation and migration. Seems to inhibit VEGFA-mediated signaling by blocking the interaction of VEGFA to its receptor KDR/VEGFR2. Modulates endothelial cell migration in an integrin-dependent manner implicating integrin ITGA5 : ITGB1 and to a lesser extent ITGAV : ITGB3 and ITGAV : ITGB5 (By similarity). May negatively regulate the activity of homotrimeric non-collagenous domain 1 (PubMed : 11257123). See full target information COL18A1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.